ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
ViiV’s cabotegravir scores breakthrough designation for HIV prevention
November 19, 2020GlaxoSmithKline subsidiary ViiV Healthcare has announced that its long-acting injectable cabotegravir has scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) for HIV prevention. -
Final data on ViiV's cabotegravir show impressive HIV PrEP
July 09, 2020ViiV's investigational, long-acting injectable cabotegravir was found to be 66% more effective than daily pills in preventing HIV-1 acquisition, according to final analysis of data from the HPTN 083 study.
Pharma Sources Insight January 2025
